WE'LL BEGIN WORKING ON ANNUAL REPORTS THIS WEEK.
ANNUAL REPORT LAYOUT:
ANNUAL REPORT LAYOUT:
PFIZZER ANNUAL REPORT 2019
PFIZER annual report 2019
letter from the president & ceo
highlights
boards of directors
our impact on people
our impact on science
our impact on the world
financial highlights: where 2018 revenues came from
teamwork & collaboration
research & development
financial statements
employees: a culture of innovation and continuous improvement
Our Impact on People
Our Impact on People
We touch people at every stage of life, every day, wherever people take their health and well being in hand. Our trusted products—from vaccines to nutrition, from self-care to life-changing and life-saving treatments—help people live healthier, longer and happier. Pfizer is with you for life.
Commited to patient Safety
Lum volor modistem nulparum quam simendit faccus, adit, qui dio. Obis simagnatur, quunditas eos se verro volupitatis explatemqui as eos ea corae quis que evellora qui nostium quassit lam aute pressequo temporernam quia quam hite nossit veribus de et vendae. Nam adit illacipsandi ipsandus in nemolup iendem cor as paria sum que ne occus nonsequi tem re cus, idiaeri anitatia dit alitaqu aectem vitata volupitat exerum esci
PREVNAR 13 helping children around the world.
Sam quo estin plaboratus acias ex explabo reptaspient auteni ut aut ad es a voluptate sent optaquodis solore consereium doluptae. Nam, tem. Nam lamus de is evelestis qui ut maximil ipsant acestruptate voluptae opta dia nis aciis a si tem non rerem explam latint, qui officiat aut venienetus, tet asperum faccum doloressit lat.
health and wellness at all stages of life
Nonseque exeriatur aut minctur aut et quodia del experat.
Sed quistibus suntur adi con pero quat laborehenis expeles sitatur? Quis et ut vel in re num qui dendus. Ed et velectur? Uditiorum adionsed quatur, iliquis voloreratis esciam
DIVERSITY AND INCLUSION
Quias aliquo cuptatem hil eatur, seque volorruptium suntis imperna tempos maionsendam, nimus re voluptatemo quiam quati deres et dolor andae dolupta sitatis cupiscient enditet alit prae et am sae corro eum venis expeditatem nate volupta nonecta temporro ipis que volori cus quam ipsam quia si aut hario. Ut ma doloriti occae voluptaque est, sam dolora pre net latae dolor aut utatist haribea verum landae exceaque pores que liquodi genecum faccus de natemporion poreperum et the end
Number of scholarships provided for veterinary students by Pfizer Animal Health in the first year of a $2 million, three-year program to support the future of the veterinary profession.
The number of years we’ve been around—helping our customers achieve better health and quality of life.
The number of countries that have approved our newest vaccine, Prevnar 13 —helping to prevent more strains of serious pneumonococcal disease in infants and young children than any other vaccine.
Letter From CEO:
and subsidary
companies
Dear Investor,
I write you this annual letter to convey how Pfizzer thinks about capital allocation, methodologies that we find useful in estimating our intrinsic value per share, and a transparent view into the successes and failures that we have had on our continuing journey to build a transformational and enduring business.
Our strategy remains the same as that which I described in my letter to you last year: Pfizzer invests in and builds customer-focused, entrepreneurial, mass customization businesses for the long term, which we manage in a decentralized, autonomous manner. We drive competitive advantage across Pfizzer through a select few shared strategic capabilities that have the greatest potential to create Pfizzer-wide value. We limit all other central activities to only those which absolutely must be performed centrally. Our uppermost financial objective is to maximize our intrinsic value per share.
Pfizzer delivers better value to customers than traditional competitors. However, we have dropped “world leader in mass customization” from our strategic articulation given that mass customization is not a market per se, but rather a competitive operational strategy which can be applied across many markets.
Over the past year we have successfully implemented three significant changes to how we run Pfizzer, plans for which I articulated to you in my last annual investor letter. These were (i) to decentralize, (ii) to align our financial management systems around unlevered free cash flow, and (iii) to narrow the focus of our mass customization platform. fit to be about $75 million
Our corporate activities that we maintain centrally in line with the above-articulated strategy.
Sincerely yours,
Eugene Bell, CEO of Pfizer
THURSDAY:
We'll talk more about Annual Reports and finish the Pfizer report.
Financial Statements
consolidated
statements of income pfizer incand subsidary
companies
You will need this copy for the table:
(Millions, except per common share data)
Revenues
Costs and Expenses
Cost of sales
Selling, administration expenses
Research and development expenses
Ammortization of intangible assets
Aquired assets
Restructuring charges
Other Income deductions
Income from continuing reparations
Provision for taxes on income
Minority interests
Income from operations
Discontinued operations
Net income
Earnings per common share - basic
Income from continuing operations
Discontinued operations
Net income
Earnings per common share-diluted
Income from continuing operations
Discontinued operations
Net income
Weighted average share-basic
Weighted average share-diluted
YEAR ENDiING DEC 31
2011
$48,626
8,112
14,527
7,985
2,668
5690
633
2,475
2,002
1203
9,848
678
807
8,700
1.19
.01
1.18
1.19
.01
1.20
6,727
6,750
2012
$52,007
8,872
13,527
6,975
2,668
580
633
2,475
2,002
1203
9,848
678
807
8,700
1.19
.01
1.18
1.19
.01
1.20
6,727
6,750
The U.S. versus the rest of the world
Pfizer is No. 1 in the top three markets for biopharmaceuticals-The U.S., the European Union and Japan.
The U.S.
REST OF THE WORLD
56.5 43.5
Developed versus emerging markets
Pfizer has a remarkable opportunity in emerging markets, and already the top U.S. headquartered biopharmaceutical company in these markets.
Developed Markets
Emerging Markets
61 39
LAB:
Finish Annual Report, hand in as mechanical file-output as spreads
Finish Annual Report, hand in as mechanical file-output as spreads
Comments
Post a Comment